RxDoctor Payments Data

Alex Taveras-Cruz, MD

General Practice · Palm Coast, FLNPI 1780645903

Payments from drug & device makers

$825in general payments, 2019–2025

Across 42 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$434
  • Novo Nordisk$294
  • Novartis$30
  • Boehringer Ingelheim$27
  • AbbVie$15
  • Bayer$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$825100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK26$434
Novo Nordisk9$294
Novartis2$30
Boehringer Ingelheim2$27
AbbVie1$15
Bayer1$13
Johnson & Johnson1$13

How this compares

$825 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$14,403
Medicare patients
33
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$92,474
InvokanaCanagliflozin77$73,539
XareltoRivaroxaban19$30,845
EntrestoSacubitril/Valsartan27$25,047
TresibaInsulin Degludec26$21,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,294
Rosuvastatin Calcium1,080$10,290
LantusInsulin Glargine,hum.Rec.Anlog57$9,576
Fenofibrate362$6,358
NovologInsulin Aspart21$5,342
Ezetimibe340$4,558
Levothyroxine Sodium543$4,479
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,346
SymbicortBudesonide/Formoterol Fumarate13$4,281
Albuterol Sulfate HfaAlbuterol Sulfate72$3,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvokana, Xarelto$13$104,38496 claims
Novo NordiskTresiba, Novolog$294$27,10247 claims
NovartisEntresto$30$25,04727 claims
GSKTrelegy Ellipta$434$18,29419 claims
AbbVieSynthroid$15$1,24512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.

Other general practice in Palm Coast

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →